PSMA-targeted imaging has demonstrated excellent sensitivity and specificity for the detection of prostate cancer compared to conventional imaging, with preliminary evidence demonstrating that the result impacts clinical practice. The gene discussed is FOLH1; the disease is prostate carcinoma.